Lifeward Ltd (LFWD)

Lifeward shares fall after Q4 results miss expectationsMarch 18, 2026 11:05 AM
IH Market News
Lifeward Ltd. (NASDAQ:LFWD) reported weaker-than-expected results for the fourth quarter of fiscal 2025, with both earnings and revenue coming in well below analyst forecasts. The disappointing performance sent the company’s shares down about 7% in premarket trading, with the stock changing hands near $7.The medical technology company reported earnings per share of -$2.85 for the quarter, compared with analyst expectations of a loss of -$0.08 per share. Revenue totaled $5.08 million, also missing estimates of $8.01 million.



Revenue pressure tied to restructuring



Lifeward said revenue declined 14% year over year, reflecting the impact of restructuring efforts in its U.S. sales and distribution operations as well as inventory timing issues.Despite the decline in sales, the company reported some operational improvement, with its GAAP gross profit margin rising to 38.2%.For the quarter, Lifeward reported GAAP gross profit of $8.4 million, while operating expenses totaled $28.1 million, representing a 25% reduction compared with the previous year.



Market reaction



Following the earnings release, Lifeward shares fell 7.28% in premarket trading. The stock has experienced significant volatility over the past year, declining sharply from a 52-week high of $23.04.At current levels, the company’s market capitalization stands at about $11.55 million. Over the past 12 months, the stock has lost roughly 61%, although it posted a short-term gain of about 13% in the previous week.



Strategic transformation underway



Lifeward is currently pursuing a broader transformation aimed at evolving into a diversified biomedical innovation company. The strategy includes expanding beyond its traditional focus on neurorehabilitation and pursuing new product opportunities and partnerships.Among these initiatives is a strategic collaboration with Oramed that includes the acquisition of the oral insulin candidate ORMD-0801. The company has also entered into a partnership involving Skelable’s technology as part of its effort to diversify its product portfolio.“Our partnership with Oramed and the acquisition of Skelable’s technology are pivotal steps in diversifying our portfolio and tapping into new markets,” said CEO Mark Grant.



Outlook and risks



Management said it remains optimistic about long-term growth prospects despite the current revenue pressures. Analyst price targets currently range from $54 to $120, implying potential upside if the company’s strategic initiatives are successfully executed.However, several risks remain. Ongoing restructuring of the company’s sales and distribution network could continue to weigh on revenue in the near term. In addition, the success of new products and partnerships remains uncertain, while macroeconomic conditions and regulatory approvals for new medical technologies could affect the pace of commercialization.



Focus on execution



During the earnings call, analysts questioned management about the company’s plans to address the revenue shortfall and when the benefits of its strategic transformation might become visible. Executives said efforts are underway to improve the sales infrastructure and broaden reimbursement coverage, which they see as key drivers of future growth.Lifeward stock price

Original: Lifeward shares fall after Q4 results miss expectations

LDWD 7 DOLLA

LFWD 6 DOLLA RING A DING DING

LFWD LETS SEE THAT 6 DOLLA

LFWD BEAST

LFWD POST RS BEASTING

LFWD post RS popping

LFWD post RS popping

.79

$LFWD: Make everyone accessible !

https://golifeward.com/products/rewalkpersonal-exoskeleton/




GO $LFWD

$LFWD: I love this company... old ReWalk

By far this has the most potential upside in the future.
Combing AI with Robotics.......... this will be a game changer in mobility for those with Special Need
and also for those with mobility issues.

Excellent time to get in here at $0.60 !!!!!!!!!


GO $LFWD

*****************************************************************************

UnitedHealthcare Medicare Advantage Plan Issues Prior Authorization Approval for a ReWalk 7 Personal Exoskeleton
By Lifeward Ltd. | November 17, 2025, 8:00 AM

Share
LFWD
+2.01%
Lifeward Ltd
Approval marks continued progress in expanding reimbursement pathways and accelerating access to advanced personal exoskeleton technology for individuals with spinal cord injury.

MARLBOROUGH, Mass. and YOKNEAM ILLIT, Israel, Nov. 17, 2025 (GLOBE NEWSWIRE) -- Lifeward Ltd., (Nasdaq: LFWD) (“Lifeward” or the “Company”), a global leader in innovative medical technology to transform the lives of people with physical limitations or disabilities, announced today that it received its first prior authorization from a UnitedHealthcare Medicare Advantage Plan for a ReWalk 7 Personal Exoskeleton.

UnitedHealthcare is fully committed to supporting its members by providing access to advanced assistive technology, as evidenced by its recent prior authorization approval for the ReWalk 7 Personal Exoskeleton. This decision reflects a proactive approach to ensuring individuals with spinal cord injury receive cutting-edge solutions that enhance mobility, independence, and quality of life.

By approving coverage for the ReWalk 7 under their Medicare Advantage Plan, UnitedHealthcare demonstrates leadership in embracing innovative medical devices and expanding reimbursement pathways for beneficiaries. The approval exemplifies its dedication to meeting the needs of members with disabilities and their families, ensuring reliable, predictable access to personal exoskeletons as part of a comprehensive care strategy.

“This prior authorization approval from a UnitedHealthcare Medicare Advantage Plan signals a significant advancement in payer adoption of the ReWalk Exoskeleton,” said Mark Grant, CEO of Lifeward. “As coverage expands and prior authorizations accelerate, we’re seeing greater predictability in reimbursement, improved cash flow dynamics, and a clearer pathway toward scalable, sustainable growth in the U.S. market.”

In 2024, the Centers for Medicare & Medicaid Services (CMS) implemented a reimbursement pathway for personal exoskeletons. Since then, Lifeward has continued to submit claims on behalf of beneficiaries enrolled in both traditional Medicare and Medicare Advantage Plans and is seeing an acceleration in prior authorizations as payer adoption expands.

About Lifeward

Lifeward designs, develops, and commercializes life-changing solutions spanning the continuum of care in physical rehabilitation and recovery, delivering proven functional and health benefits in clinical settings, as well as in the home and community. Our mission at Lifeward is to relentlessly drive innovation to change the lives of individuals with physical limitations or disabilities. We are committed to delivering groundbreaking solutions that empower individuals to do what they love. The Lifeward portfolio features innovative products, including the ReWalk Exoskeleton, AlterG Anti-Gravity System, ReStore Exo-Suit, and MyoCycle FES System. Founded in 2001, Lifeward has operations in the United States, Israel, and Germany.

Lifeward®, ReWalk®, ReStore®, and Alter G® are registered trademarks of Lifeward Ltd. and/or its affiliates.

Forward-Looking Statements

In addition to historical information, this press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, Section 27A of the U.S. Securities Act of 1933, and Section 21E of the U.S. Securities Exchange Act of 1934. Such forward looking statements may include projections regarding the Company's future performance and other statements that are not statements of historical fact and, in some cases, may be identified by words like "anticipate," "assume," "believe," "continue," "could," "estimate," "expect," "intend," "may," "plan," "potential," "predict," "project," "future," "will," "should," "would," "seek" and similar terms or phrases. The forward-looking statements contained in this press release are based on management's current expectations, which are subject to uncertainty, risks and changes in circumstances that are difficult to predict and many of which are outside of the Company’s control. Important factors that could cause the Company’s actual results to differ materially from those indicated in the forward looking statements include, among others: the acceptance of the ReWalk 7 Personal Exoskeleton by healthcare professionals and patients; uncertainties associated with future clinical trials and the clinical development process, the product development process and FDA regulatory submission review and approval process; the Company's ability to have sufficient funds to meet certain future capital requirements, which could impair the Company's efforts to develop and commercialize existing and new products; the Company's ability to maintain and grow its reputation and the market acceptance of its products; the Company's ability to achieve reimbursement from third-party payors, including CMS, for its products; the Company's limited operating history and its ability to leverage its sales, marketing and training infrastructure; the Company's expectations as to its clinical research program and clinical results; the Company's expectations regarding future growth, including its ability to increase sales in its existing geographic markets and expand to new markets; the Company's ability to obtain certain components of its products from third-party suppliers and its continued access to its product manufacturers; the Company’s ability to navigate any difficulties associated with moving production of its AlterG Anti-Gravity Systems to a contract manufacturer and transitioning the manufacturing of its ReWalk products to its in-house manufacturer; the Company's ability to improve its products and develop new products; the Company's compliance with medical device reporting regulations to report adverse events involving the Company's products, which could result in voluntary corrective actions or enforcement actions such as mandatory recalls, and the potential impact of such adverse events on the Company's ability to market and sell its products; the Company's ability to gain and maintain regulatory approvals; the Company's ability to maintain adequate protection of its intellectual property and to avoid violation of the intellectual property rights of others; the risk of a cybersecurity attack or breach of the Company's IT systems significantly disrupting its business operations; the Company's ability to use effectively the proceeds of its offerings of securities; and other factors discussed under the heading "Risk Factors" in the Company’s annual report on Form 10-K, as amended, for the year ended December 31, 2024 filed with the SEC and other documents subsequently filed with or furnished to the SEC. Any forward-looking statement made in this press release speaks only as of the date hereof. Factors or events that could cause the Company’s actual results to differ from the statements contained herein may emerge from time to time, and it is not possible for the Company to predict all of them. Except as required by law, the Company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future developments or otherwise.

Lifeward Media Relations:
Almog Adar
Chief Financial Officer
E: media@golifeward.com

Lifeward Investor Contact:
Almog Adar
Chief Financial Officer
Lifeward
E: ir@golifeward.com

This FDA news is very very nice

Anytime a ticker gets "upgrades" from investment houses, and ticker has been in a yearlong down trend, run the other way, or, get in and get out. Hope you all cut your losses.
Never trust the word of any investment house.

LFWD READY TO RUN AGAIN

$LFWD: Trying for 3 crack here..............

quite the boost already.

Up 80% on the day thus far

GO $LFWD

$LFWD: Shes rolling now............ up to $2.40

Wow................... those are some big legs......... and that was a massive 4Milly vol print

MAMA

GO $LFWD

LFWD FAKE THE MAGNET...MOVE INTO NOTE

LFWD NEXT MAGNET 3.07

LFWD BREAKING 2.63 MAGNET

LFWD 2.63 MAGNET HIT...PRECISION CHARTING BY A MASTER

LFWD 2.63 MAGNET

LFWD MONSTER MOVING

LFWD STRONG GAPPER

LFWD MONSTER

LFWD BIG GAPPA

LFWD INTO NEXT WEEK MONSTER COMING

Exoskeleton in the $2s

Nice bump today $1.89

LFWD

Robotics Stock #3: Lifeward

Founded in 2001, Israel-based Lifeward Ltd. (LFWD), formerly known as ReWalk Robotics, is at the forefront of transforming physical rehabilitation and recovery with innovative solutions that enhance care from clinical settings to home and community. Driven by a mission to revolutionize the lives of those with physical limitations or disabilities, Lifeward delivers cutting-edge products like the ReWalk Exoskeleton, AlterG Anti-Gravity systems, ReStore Exo-Suit, and MyoCycle FES Systems.

With a market cap of around $27.4 million, shares of Lifeward have pulled back about 42% on a YTD basis.


www.barchart.com
On Aug. 15, shares of Lifeward shot up more than 30% after the company reported stronger-than-expected Q2 earnings. The company’s revenue of $6.7 million reflected a massive 400% year-over-year jump, narrowly edging past Wall Street’s consensus estimate. Lifeward reported a loss per share of $0.50 in Q2, slightly better than Wall Street’s forecast for a loss per share of $0.53.

Top-line growth was fueled by ReWalk system revenue, primarily driven by the expansion of access through Medicare coverage, marking a significant milestone for the company. CEO Larry Jasinski highlighted the company's progress in establishing a Medicare processing pipeline and achieving successful payments.

As of June 30, the company maintained a healthy $15.1 million unrestricted cash and cash equivalents with zero debt on the books. Delays in Medicare payments impacted operational cash outflows of $5.6 million in Q2, but with $2.6 million in receivables for Medicare claims now starting to come through, the company is poised for improved cash flow in the upcoming quarters.

Encouraged by the strong Q2 performance, management reaffirmed its fiscal 2024 revenue outlook, projecting it to range between $28 million and $32 million. With expanded access to ReWalk systems thanks to newly established Medicare coverage and increasing sales momentum from its revamped commercial team, management anticipates steady quarterly revenue growth for the remainder of fiscal 2024.

LFWD stock has a unanimous “Strong Buy” rating from just two analysts offering recommendations, with the price target of $13 indicating expected upside potential of about 315%.